Symbols / MBRX $2.32 +4.04% Moleculin Biotech, Inc.
MBRX Chart
About
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.38M |
| Enterprise Value | 3.86M | Income | -33.66M | Sales | — |
| Book/sh | 4.69 | Cash/sh | 1.66 | Dividend Yield | — |
| Payout | 0.00% | Employees | 17 | IPO | — |
| P/E | — | Forward P/E | -0.02 | PEG | — |
| P/S | — | P/B | 0.49 | P/C | — |
| EV/EBITDA | -0.15 | EV/Sales | — | Quick Ratio | 1.30 |
| Current Ratio | 1.41 | Debt/Eq | 2.39 | LT Debt/Eq | — |
| EPS (ttm) | -28.42 | EPS next Y | -110.50 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 16:00 | ROA | -80.35% |
| ROE | -256.05% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 5.34M |
| Shs Float | 5.29M | Short Float | 2.07% | Short Ratio | 0.38 |
| Short Interest | — | 52W High | 28.60 | 52W Low | 1.79 |
| Beta | 1.67 | Avg Volume | 167.50K | Volume | 59.66K |
| Target Price | $21.00 | Recom | Strong_buy | Prev Close | $2.23 |
| Price | $2.32 | Change | 4.04% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-24 | reit | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-12-11 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-09-10 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-06-18 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-03-25 | up | Maxim Group | Hold → Buy | $4 |
| 2025-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-24 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-03-03 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-12 | main | Maxim Group | Buy → Buy | $8 |
| 2024-04-12 | main | Roth MKM | Buy → Buy | $40 |
| 2024-03-26 | main | Maxim Group | Buy → Buy | $20 |
| 2023-12-14 | init | HC Wainwright & Co. | — → Buy | $3 |
| 2023-04-18 | main | Roth MKM | — → Buy | $16 |
| 2023-03-24 | reit | Oppenheimer | — → Outperform | $5 |
- MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill hu, 02 Apr 2026 07
- Leukemia trial update: Moleculin CEO explains MIRACLE drug study - Stock Titan Wed, 11 Mar 2026 07
- Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025 - Quiver Quantitative Wed, 26 Nov 2025 08
- MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish - Bitget Sun, 30 Nov 2025 08
- Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN ue, 31 Mar 2026 22
- Why Did MBRX Stock Climb 14% Today? - Stocktwits Wed, 18 Feb 2026 18
- MBRX Forecast, Price Target & Analyst Ratings | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill hu, 02 Apr 2026 07
- Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan hu, 19 Mar 2026 07
- $MBRX stock is down 17% today. Here's what we see in our data. - Quiver Quantitative Wed, 17 Dec 2025 08
- MBRX Stock Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill ue, 31 Mar 2026 07
- Moleculin leaders set for March 24 ROTH healthcare investor chat - Stock Titan ue, 17 Mar 2026 07
- If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan Sun, 22 Mar 2026 11
- Experimental chemo aiming to spare the heart nears key 2026 trial test - Stock Titan Mon, 12 Jan 2026 08
- Chemo without heart damage? Leukemia drug trial sees 40% remission rate - Stock Titan Wed, 18 Feb 2026 08
- Leukemia drug study reaches key 45-patient mark with results due mid-2026 - Stock Titan Mon, 23 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
25.10
-5.77%
|
26.64
-10.09%
|
29.63
-3.29%
|
30.64
|
| Research And Development |
|
15.89
-10.37%
|
17.73
-9.02%
|
19.49
+2.74%
|
18.97
|
| Selling General And Administration |
|
9.12
+3.82%
|
8.79
-12.29%
|
10.02
-13.21%
|
11.54
|
| General And Administrative Expense |
|
9.12
+3.82%
|
8.79
-12.29%
|
10.02
-13.21%
|
11.54
|
| Other Gand A |
|
9.12
+3.82%
|
8.79
-12.29%
|
10.02
-13.21%
|
11.54
|
| Total Expenses |
|
25.10
-5.77%
|
26.64
-10.09%
|
29.63
-3.29%
|
30.64
|
| Operating Income |
|
-25.10
+5.77%
|
-26.64
+10.09%
|
-29.63
+3.29%
|
-30.64
|
| Total Operating Income As Reported |
|
-25.10
+5.77%
|
-26.64
+10.09%
|
-29.63
+3.29%
|
-30.64
|
| EBITDA |
|
-25.01
+5.66%
|
-26.52
+10.13%
|
-29.50
+3.30%
|
-30.51
|
| Normalized EBITDA |
|
-16.47
+37.88%
|
-26.52
+5.13%
|
-27.95
+12.23%
|
-31.84
|
| Reconciled Depreciation |
|
0.09
-28.57%
|
0.13
-0.79%
|
0.13
-2.31%
|
0.13
|
| EBIT |
|
-25.10
+5.77%
|
-26.64
+10.09%
|
-29.63
+3.29%
|
-30.64
|
| Total Unusual Items |
|
-8.54
|
0.00
+100.00%
|
-1.55
-216.40%
|
1.33
|
| Total Unusual Items Excluding Goodwill |
|
-8.54
|
0.00
+100.00%
|
-1.55
-216.40%
|
1.33
|
| Special Income Charges |
|
-0.61
|
0.00
|
—
|
—
|
| Other Special Charges |
|
0.61
|
—
|
—
|
—
|
| Net Income |
|
-33.56
-28.84%
|
-26.05
+12.50%
|
-29.77
-2.56%
|
-29.02
|
| Pretax Income |
|
-33.56
-28.84%
|
-26.05
+12.50%
|
-29.77
-2.56%
|
-29.02
|
| Net Non Operating Interest Income Expense |
|
0.10
-80.91%
|
0.55
-59.80%
|
1.37
+470.00%
|
0.24
|
| Net Interest Income |
|
0.10
-80.91%
|
0.55
-59.80%
|
1.37
+470.00%
|
0.24
|
| Interest Income Non Operating |
|
0.10
-80.91%
|
0.55
-59.80%
|
1.37
+470.00%
|
0.24
|
| Interest Income |
|
0.10
-80.91%
|
0.55
-59.80%
|
1.37
+470.00%
|
0.24
|
| Other Income Expense |
|
-8.56
-20011.63%
|
0.04
+102.86%
|
-1.51
-209.53%
|
1.38
|
| Other Non Operating Income Expenses |
|
-0.02
-146.51%
|
0.04
-10.42%
|
0.05
+20.00%
|
0.04
|
| Gain On Sale Of Security |
|
-7.93
-285.02%
|
4.29
+375.74%
|
-1.55
-216.40%
|
1.33
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-33.56
-28.84%
|
-26.05
+12.50%
|
-29.77
-2.56%
|
-29.02
|
| Net Income From Continuing Operation Net Minority Interest |
|
-33.56
-28.84%
|
-26.05
+12.50%
|
-29.77
-2.56%
|
-29.02
|
| Net Income From Continuing And Discontinued Operation |
|
-33.56
-28.84%
|
-26.05
+12.50%
|
-29.77
-2.56%
|
-29.02
|
| Net Income Continuous Operations |
|
-33.56
-28.84%
|
-26.05
+12.50%
|
-29.77
-2.56%
|
-29.02
|
| Normalized Income |
|
-25.02
+3.95%
|
-26.05
+7.68%
|
-28.21
+7.07%
|
-30.36
|
| Net Income Common Stockholders |
|
-33.66
-29.24%
|
-26.05
+12.50%
|
-29.77
-2.56%
|
-29.02
|
| Otherunder Preferred Stock Dividend |
|
0.10
|
0.00
|
—
|
—
|
| Diluted EPS |
|
—
|
-189.14
+49.80%
|
-376.75
+0.53%
|
-378.75
|
| Basic EPS |
|
—
|
-189.14
+49.80%
|
-376.75
+0.53%
|
-378.75
|
| Basic Average Shares |
|
—
|
0.14
+74.28%
|
0.08
+3.60%
|
0.08
|
| Diluted Average Shares |
|
—
|
0.14
+74.28%
|
0.08
+3.60%
|
0.08
|
| Diluted NI Availto Com Stockholders |
|
-33.66
-29.24%
|
-26.05
+12.50%
|
-29.77
-2.56%
|
-29.02
|
| Depreciation Amortization Depletion Income Statement |
|
0.09
-28.57%
|
0.13
-0.79%
|
0.13
-2.31%
|
0.13
|
| Depreciation And Amortization In Income Statement |
|
0.09
-28.57%
|
0.13
-0.79%
|
0.13
-2.31%
|
0.13
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
22.13
+30.73%
|
16.93
-55.71%
|
38.22
-33.45%
|
57.42
|
| Current Assets |
|
9.69
+86.48%
|
5.19
-80.23%
|
26.27
-42.38%
|
45.60
|
| Cash Cash Equivalents And Short Term Investments |
|
8.88
+107.53%
|
4.28
-81.83%
|
23.55
-45.42%
|
43.15
|
| Cash And Cash Equivalents |
|
8.88
+107.53%
|
4.28
-81.83%
|
23.55
-45.42%
|
43.15
|
| Receivables |
|
0.01
-65.00%
|
0.02
-79.80%
|
0.10
+350.00%
|
0.02
|
| Other Receivables |
|
0.01
-65.00%
|
0.02
-78.95%
|
0.10
+4650.00%
|
0.00
|
| Prepaid Assets |
|
0.80
-10.60%
|
0.90
-65.85%
|
2.62
+8.03%
|
2.43
|
| Total Non Current Assets |
|
12.44
+6.04%
|
11.73
-1.78%
|
11.94
+1.00%
|
11.83
|
| Net PPE |
|
0.39
-32.76%
|
0.58
-26.76%
|
0.80
+17.40%
|
0.68
|
| Gross PPE |
|
0.39
-32.76%
|
0.58
-65.54%
|
1.69
+16.93%
|
1.45
|
| Accumulated Depreciation |
|
—
|
-1.02
-14.06%
|
-0.90
-16.51%
|
-0.77
|
| Machinery Furniture Equipment |
|
0.08
-50.94%
|
0.16
-86.39%
|
1.17
+11.88%
|
1.04
|
| Other Properties |
|
0.31
-25.94%
|
0.42
-19.08%
|
0.52
+30.02%
|
0.40
|
| Goodwill And Other Intangible Assets |
|
11.15
+0.00%
|
11.15
+0.00%
|
11.15
+0.00%
|
11.15
|
| Other Intangible Assets |
|
11.15
+0.00%
|
11.15
+0.00%
|
11.15
|
—
|
| Non Current Prepaid Assets |
|
0.90
|
0.00
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
7.12
+24.54%
|
5.72
-52.92%
|
12.14
+132.15%
|
5.23
|
| Current Liabilities |
|
6.85
+27.90%
|
5.36
-21.36%
|
6.82
+41.42%
|
4.82
|
| Payables And Accrued Expenses |
|
6.72
+28.21%
|
5.24
-21.98%
|
6.71
+42.78%
|
4.70
|
| Payables |
|
3.51
+72.81%
|
2.03
-20.64%
|
2.56
+17.29%
|
2.18
|
| Accounts Payable |
|
3.51
+72.81%
|
2.03
-18.73%
|
2.50
+19.24%
|
2.10
|
| Current Accrued Expenses |
|
3.21
+0.00%
|
3.21
-22.80%
|
4.16
+64.83%
|
2.52
|
| Current Debt And Capital Lease Obligation |
|
0.14
+14.17%
|
0.12
+20.00%
|
0.10
-13.79%
|
0.12
|
| Current Capital Lease Obligation |
|
0.14
+14.17%
|
0.12
+20.00%
|
0.10
-13.79%
|
0.12
|
| Total Non Current Liabilities Net Minority Interest |
|
0.27
-25.70%
|
0.36
-93.28%
|
5.33
+1193.45%
|
0.41
|
| Long Term Debt And Capital Lease Obligation |
|
0.22
-37.99%
|
0.36
-24.47%
|
0.47
+41.49%
|
0.34
|
| Long Term Capital Lease Obligation |
|
0.22
-37.99%
|
0.36
-24.47%
|
0.47
+41.49%
|
0.34
|
| Stockholders Equity |
|
15.01
+33.89%
|
11.21
-57.01%
|
26.07
-50.04%
|
52.19
|
| Common Stock Equity |
|
15.01
+33.89%
|
11.21
-57.01%
|
26.07
-50.04%
|
52.19
|
| Capital Stock |
|
0.00
|
0.00
-100.00%
|
0.03
+13.79%
|
0.03
|
| Common Stock |
|
0.00
|
0.00
-100.00%
|
0.03
+13.79%
|
0.03
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
3.20
+2267.08%
|
0.14
+51.69%
|
0.09
+16.71%
|
0.08
|
| Ordinary Shares Number |
|
3.20
+2267.08%
|
0.14
+51.69%
|
0.09
+16.71%
|
0.08
|
| Additional Paid In Capital |
|
221.00
+20.31%
|
183.69
+16.52%
|
157.65
+2.38%
|
153.99
|
| Retained Earnings |
|
-206.00
-19.46%
|
-172.44
-31.03%
|
-131.60
-29.23%
|
-101.83
|
| Gains Losses Not Affecting Retained Earnings |
|
0.01
+124.39%
|
-0.04
-355.56%
|
-0.01
-175.00%
|
0.01
|
| Other Equity Adjustments |
|
0.01
+124.39%
|
-0.04
-355.56%
|
-0.01
-175.00%
|
0.01
|
| Total Equity Gross Minority Interest |
|
15.01
+33.89%
|
11.21
-57.01%
|
26.07
-50.04%
|
52.19
|
| Total Capitalization |
|
15.01
+33.89%
|
11.21
-57.01%
|
26.07
-50.04%
|
52.19
|
| Working Capital |
|
2.83
+1816.36%
|
-0.17
-100.85%
|
19.46
-52.28%
|
40.78
|
| Invested Capital |
|
15.01
+33.89%
|
11.21
-57.01%
|
26.07
-50.04%
|
52.19
|
| Total Debt |
|
0.36
-24.90%
|
0.48
-16.72%
|
0.57
+27.27%
|
0.45
|
| Capital Lease Obligations |
|
0.36
-24.90%
|
0.48
-16.72%
|
0.57
+27.27%
|
0.45
|
| Net Tangible Assets |
|
3.86
+6330.00%
|
0.06
-99.60%
|
14.93
-63.64%
|
41.04
|
| Tangible Book Value |
|
3.86
+6330.00%
|
0.06
-99.60%
|
14.93
-63.64%
|
41.04
|
| Derivative Product Liabilities |
|
0.04
|
0.00
-100.00%
|
4.86
+6205.19%
|
0.08
|
| Duefrom Related Parties Current |
|
—
|
0.00
+0.00%
|
0.00
-80.00%
|
0.02
|
| Dueto Related Parties Current |
|
—
|
0.13
+116.67%
|
0.06
-30.23%
|
0.09
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-22.73
+4.72%
|
-23.86
-1.15%
|
-23.59
+14.65%
|
-27.64
|
| Cash Flow From Continuing Operating Activities |
|
-22.73
+4.72%
|
-23.86
-1.15%
|
-23.59
+14.65%
|
-27.64
|
| Net Income From Continuing Operations |
|
-33.56
-28.84%
|
-26.05
+12.50%
|
-29.77
-2.56%
|
-29.02
|
| Depreciation Amortization Depletion |
|
0.09
-28.57%
|
0.13
-0.79%
|
0.13
-2.31%
|
0.13
|
| Depreciation And Amortization |
|
0.09
-28.57%
|
0.13
-0.79%
|
0.13
-2.31%
|
0.13
|
| Other Non Cash Items |
|
-0.03
-125.24%
|
0.10
-88.44%
|
0.89
+868.48%
|
0.09
|
| Stock Based Compensation |
|
1.66
-3.59%
|
1.73
-13.00%
|
1.98
-12.79%
|
2.27
|
| Operating Gains Losses |
|
8.54
+299.35%
|
-4.29
-375.74%
|
1.55
+216.40%
|
-1.33
|
| Gain Loss On Investment Securities |
|
8.54
+299.35%
|
-4.29
-375.74%
|
1.55
+216.40%
|
-1.33
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.56
+140.26%
|
0.23
-85.76%
|
1.62
+624.11%
|
0.22
|
| Change In Prepaid Assets |
|
-0.79
-143.83%
|
1.81
+764.34%
|
-0.27
+68.26%
|
-0.86
|
| Change In Payables And Accrued Expense |
|
1.35
+185.47%
|
-1.58
-183.21%
|
1.89
+75.21%
|
1.08
|
| Change In Accrued Expense |
|
0.02
+101.53%
|
-1.11
-174.31%
|
1.49
+326.00%
|
0.35
|
| Change In Payable |
|
1.33
+384.19%
|
-0.47
-216.13%
|
0.40
-44.87%
|
0.73
|
| Change In Account Payable |
|
1.33
+384.19%
|
-0.47
-216.13%
|
0.40
-44.87%
|
0.73
|
| Investing Cash Flow |
|
0.00
+100.00%
|
-0.01
+89.52%
|
-0.12
-85.07%
|
-0.07
|
| Cash Flow From Continuing Investing Activities |
|
0.00
+100.00%
|
-0.01
+89.52%
|
-0.12
-85.07%
|
-0.07
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.01
+89.52%
|
-0.12
-85.07%
|
-0.07
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.01
+89.52%
|
-0.12
-85.07%
|
-0.07
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
—
|
-0.01
+89.52%
|
-0.12
-85.07%
|
-0.07
|
| Financing Cash Flow |
|
27.28
+488.65%
|
4.63
+11.93%
|
4.14
+18104.35%
|
-0.02
|
| Cash Flow From Continuing Financing Activities |
|
27.28
+488.65%
|
4.63
+11.93%
|
4.14
+18104.35%
|
-0.02
|
| Net Common Stock Issuance |
|
25.77
+452.90%
|
4.66
+11.86%
|
4.17
|
0.00
|
| Proceeds From Stock Option Exercised |
|
1.53
+152600.00%
|
0.00
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-0.01
+69.23%
|
-0.03
-4.00%
|
-0.03
-8.70%
|
-0.02
|
| Changes In Cash |
|
4.55
+123.64%
|
-19.24
+1.71%
|
-19.57
+29.41%
|
-27.73
|
| Effect Of Exchange Rate Changes |
|
0.05
+259.38%
|
-0.03
-52.38%
|
-0.02
+27.59%
|
-0.03
|
| Beginning Cash Position |
|
4.28
-81.83%
|
23.55
-45.42%
|
43.15
-39.15%
|
70.90
|
| End Cash Position |
|
8.88
+107.53%
|
4.28
-81.83%
|
23.55
-45.42%
|
43.15
|
| Free Cash Flow |
|
-22.73
+4.77%
|
-23.88
-0.67%
|
-23.71
+14.40%
|
-27.71
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
25.77
+452.90%
|
4.66
+11.86%
|
4.17
|
0.00
|
| Issuance Of Capital Stock |
|
25.77
+452.90%
|
4.66
+11.86%
|
4.17
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-23 View
- 8-K2026-03-19 View
- 8-K2026-03-19 View
- 10-K2026-03-18 View
- 8-K2026-02-20 View
- 8-K2026-02-18 View
- 8-K2026-02-18 View
- 8-K2026-02-17 View
- 8-K2026-02-05 View
- 8-K2026-01-20 View
- 8-K2026-01-13 View
- 8-K2026-01-12 View
- 8-K2026-01-07 View
- 8-K2025-12-22 View
- 8-K2025-12-17 View
- 8-K2025-12-16 View
- 8-K2025-12-10 View
- 8-K2025-12-09 View
- 8-K2025-12-08 View
- 8-K2025-11-28 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|